Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company owns a pipeline of pharmacological inhibitors, including AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; AEF0217, a drug candidate, which is in phase 1/2 clinical trials to treat cognitive deficits observed in down syndrome; and CB1-SSi, a new molecular entities to treat other CB1-dependent diseases, including several orphan diseases. Aelis Farma SA was incorporated in 2013 and is headquartered in Bordeaux, France.